LENZ Therapeutics (LENZ) News Today $41.33 +0.52 (+1.27%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$41.02 -0.31 (-0.74%) As of 09/12/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock LENZ Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 Time Period LENZ Therapeutics, Inc. (LENZ) Therapeutics, Inc. Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptSeptember 10, 2025 | seekingalpha.com537,738 Shares in LENZ Therapeutics, Inc. $LENZ Acquired by Adage Capital Partners GP L.L.C.September 8, 2025 | marketbeat.comGranahan Investment Management LLC Acquires 124,324 Shares of LENZ Therapeutics, Inc. $LENZSeptember 7, 2025 | marketbeat.comLENZ Therapeutics, Inc. (LENZ) Therapeutics, Inc. Presents At Citi's Biopharma Back To School Conference TranscriptSeptember 3, 2025 | seekingalpha.comScoggin Management LP Purchases Shares of 100,000 LENZ Therapeutics, Inc. $LENZSeptember 3, 2025 | marketbeat.comParadigm Biocapital Advisors LP Boosts Holdings in LENZ Therapeutics, Inc. $LENZSeptember 2, 2025 | marketbeat.comAlphaQuest LLC Buys New Position in LENZ Therapeutics, Inc. $LENZSeptember 2, 2025 | marketbeat.comNuveen LLC Invests $1.72 Million in LENZ Therapeutics, Inc. $LENZSeptember 1, 2025 | marketbeat.comLENZ Therapeutics, Inc. $LENZ Shares Acquired by Vanguard Group Inc.August 30, 2025 | marketbeat.comLENZ Therapeutics: Adjusting My Position After Almost Doubling In Four MonthsAugust 28, 2025 | seekingalpha.comLENZ Therapeutics (NASDAQ:LENZ) Sees Strong Trading Volume - Here's What HappenedAugust 27, 2025 | marketbeat.comFDA Approves Eye Drops That Fix Near Vision Without GlassesAugust 25, 2025 | yahoo.comLENZ Therapeutics to Present at Upcoming Investor and Medical ConferencesAugust 25, 2025 | markets.businessinsider.comWill FDA Approval of Vizz Eye Drops Change LENZ Therapeutics' (LENZ) Narrative?August 21, 2025 | finance.yahoo.comNew FDA approved eye drops for vision is coming soonAugust 19, 2025 | msn.comLord Abbett & CO. LLC Makes New Investment in LENZ Therapeutics, Inc. (NASDAQ:LENZ)August 19, 2025 | marketbeat.comNo Need For Reading Glasses? Vizz Eye Drop That Improves Near Vision Has FDA NodAugust 18, 2025 | msn.comLENZ Therapeutics (NASDAQ:LENZ) Sees Unusually-High Trading Volume - Time to Buy?August 17, 2025 | marketbeat.comLENZ Therapeutics, Inc. (NASDAQ:LENZ) Given Consensus Recommendation of "Buy" by BrokeragesAugust 16, 2025 | marketbeat.comFDA Approves Vizz, First Daily Eye Drop For Age-Related Blurry VisionAugust 15, 2025 | msn.comLENZ Therapeutics Scores Relative Strength Rating UpgradeAugust 14, 2025 | msn.comLENZ Therapeutics (NASDAQ:LENZ) Trading Down 7.6% - Should You Sell?August 14, 2025 | marketbeat.comLENZ Therapeutics (NASDAQ:LENZ) Reaches New 52-Week High - Still a Buy?August 12, 2025 | marketbeat.comWilliam Blair Sticks to Their Buy Rating for LENZ Therapeutics (LENZ)August 10, 2025 | theglobeandmail.comNow you don’t need reading glasses, new FDA-approved eye drops can sharpen near visionAugust 9, 2025 | msn.comLENZ Therapeutics Shows Rising Price Performance With Jump To 85 RS RatingAugust 8, 2025 | msn.comDitch your glasses - breakthrough eye drops approved by FDA to fix your near vision instantlyAugust 8, 2025 | msn.comWestfield Capital Management Co. LP Invests $261,000 in LENZ Therapeutics, Inc. (NASDAQ:LENZ)August 7, 2025 | marketbeat.comLENZ Therapeutics (LENZ) Expected to Announce Earnings on WednesdayAugust 7, 2025 | marketbeat.comStocks With Rising Relative Price Strength: LENZ TherapeuticsAugust 7, 2025 | msn.comLENZ Therapeutics (NASDAQ:LENZ) Shares Down 3.6% - Time to Sell?August 5, 2025 | marketbeat.comFDA Approves Vizz Eye Drops to Improve Near Vision in AdultsAugust 5, 2025 | msn.comTD Asset Management Inc Has $895,000 Holdings in LENZ Therapeutics, Inc. (NASDAQ:LENZ)August 5, 2025 | marketbeat.comHC Wainwright Brokers Boost Earnings Estimates for LENZAugust 4, 2025 | marketbeat.comAnalysts Are Bullish on These Healthcare Stocks: LENZ Therapeutics (LENZ), GE Healthcare Technologies Inc (GEHC)August 3, 2025 | theglobeandmail.comAnalysts Offer Insights on Healthcare Companies: LENZ Therapeutics (LENZ) and Regeneron (REGN)August 3, 2025 | theglobeandmail.comLENZ Therapeutics (NASDAQ:LENZ) Sees Strong Trading Volume on Analyst UpgradeAugust 2, 2025 | marketbeat.comNovel Eye Drops for Age-Related Blurry Vision Win FDA ApprovalAugust 2, 2025 | msn.comWilliam Blair Analysts Lower Earnings Estimates for LENZAugust 2, 2025 | marketbeat.comLENZ Therapeutics (NASDAQ:LENZ) Stock Price Expected to Rise, Raymond James Financial Analyst SaysAugust 1, 2025 | marketbeat.comLENZ Therapeutics Gains FDA Approval for VIZZ Eye DropJuly 31, 2025 | msn.comLenz (LENZ) Q2 Revenue Jumps 604%July 31, 2025 | theglobeandmail.comLenz Therapeutics Prepares for LNZ100 LaunchJuly 31, 2025 | msn.comLenz Therapeutics stock rises after FDA approves presbyopia eye dropsJuly 31, 2025 | za.investing.comLENZ Therapeutics Announces US FDA Approval of VIZZ™ for the Treatment of PresbyopiaJuly 31, 2025 | globenewswire.comLENZ Therapeutics (NASDAQ:LENZ) Issues Quarterly Earnings ResultsJuly 31, 2025 | marketbeat.comFY2025 EPS Estimate for LENZ Therapeutics Boosted by AnalystJuly 31, 2025 | marketbeat.comLENZ Therapeutics shares climb as FDA review of presbyopia treatment stays on scheduleJuly 30, 2025 | msn.comLENZ Therapeutics shares surge as FDA review of presbyopia drug on trackJuly 30, 2025 | investing.comLENZ Therapeutics: Undervalued Ahead Of PDUFAJuly 29, 2025 | seekingalpha.com Get LENZ Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LENZ and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. LENZ Media Mentions By Week LENZ Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. LENZ News Sentiment▼1.570.93▲Average Medical News Sentiment LENZ News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. LENZ Articles This Week▼34▲LENZ Articles Average Week Get the Latest News and Ratings for LENZ and Related Stocks Enter your email address to receive the latest news and analysts' ratings for LENZ Therapeutics and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies PTCT News Today KRYS News Today PCVX News Today ACAD News Today ACLX News Today ADMA News Today ARWR News Today MENS News Today MIRM News Today MLTX News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:LENZ) was last updated on 9/15/2025 by MarketBeat.com Staff From Our PartnersOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding LENZ Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share LENZ Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
